This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronaryarterydisease (CAD). Information on GLD (dispended 6 months before or after coronary angiography) was collected from the Swedish Prescribed Drug Registry.
4] "Many patients taking antiplatelet therapy are simply not prescribed anticoagulants because of the fear of bleeding, leaving them without protection from the risk of stroke,” said Dan Bloomfield, MD, chief medical officer of Anthos Therapeutics. incidence rate for rivaroxaban to a 3.5% incidence rate for abelacimab 150 mg). [1] vs 4.6%).
University of Virginia School of Medicine researchers have created an "atlas of atherosclerosis" that reveals, at the level of individual cells, critical processes responsible for forming the harmful plaque buildup that causes heart attacks, strokes, and coronaryarterydisease.
Patients with atrial fibrillation are at high risk for stroke, and international guidelines recommend oral anticoagulant therapy. In patients with stable vascular disease without atrial fibrillation, antiplatelet therapy is recommended. When patients with both conditions present with.
We aimed to perform a systematic review and meta-analysis to study the effects of colchicine in patients with symptomatic coronaryarterydisease (CAD) who have undergone PCI. These results were driven mainly by the reduction in repeat vessel revascularisation, stroke and stent thrombosis.
to 1.45) for insomnia on stroke to 1.55 (95% CI 1.28 to 1.45) for insomnia on stroke to 1.55 (95% CI 1.28 MDD also partially mediated the causal effects of insomnia on stroke, sleep duration on CAD, MI and HF, daytime napping on HF and daytime sleepiness on CAD. to 1.89) for insomnia on MI. to 1.89) for insomnia on MI.
ObjectivesRevascularization in patients with severely reduced left ventricular function and coronaryarterydisease (CAD) is associated with a high perioperative risk. The in-hospital stroke rate was similar (LVAD 7 [5.4%] vs. CABG 8 [6.2%], p = 0.9). In-hospital survival, 1-year survival, and 3-year survival were 90.5%
Around the world, most people are regularly exposed to low or moderate levels of lead, cadmium and arsenic in the environment, increasing risk of coronaryarterydisease, stroke and peripheral arterydisease, according to a new statement.
Hypertension represents a major modifiable risk factor for coronaryarterydisease (CAD), heart failure (HF), stroke, chronic kidney disease (CKD), and dementia.
Stroke, Volume 55, Issue Suppl_1 , Page A9-A9, February 1, 2024. Pooled analysis of primary and secondary endpoints showed that Colchicine significantly reduced the risk of incidence of stroke by 50% (OR, 0.50 (95%CI: 0.31-0.81), 0.84), P>0.001), new acute coronary syndrome by 53% (OR, 0.47(95%CI:
This condition can lead to various complications, including stroke and heart failure, making it essential to understand its causes, symptoms, and AFib treatment options. CoronaryArteryDisease : Blocked arteries can affect heart function and rhythm. If a clot travels to the brain, it can result in a stroke.
Elevated urinary albumin excretion indicates kidney damage and systemic vascular disease, including myocardial capillary disease and arterial stiffness. Albuminuria is associated with an increased risk of coronaryarterydisease, stroke, heart failure, arrhythmias, and microvascular disease.
Researchers have discovered that the smooth muscle cells that line the arteries of people with atherosclerosis can change into new cell types and develop traits similar to cancer that worsen the disease.
The technology applies advanced AI algorithms to routine coronary computed tomography angiography (CCTA) scans to visualize and quantify coronary inflammation, the otherwise invisible disease mechanism responsible for many fatal heart attacks and strokes. fold higher risk for cardiac mortality and 5.5-fold
BackgroundIn the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, atorvastatin (80 mg per day) was compared with placebo in patients with recent stroke or transient ischemic attack and no known coronaryarterydisease. Journal of the American Heart Association, Ahead of Print.
This damage accelerates the formation of plaques, leading to atherosclerosisa condition where arteries narrow and harden, restricting blood flow. Increased Blood Clot Risk: Smoking enhances the bloods clotting tendency, raising the risk of heart attacks and strokes.
Artery Damage : Hypertension damages the inner lining of your arteries, making them less elastic and more prone to plaque buildup. This condition, called atherosclerosis, narrows the arteries, restricting blood flow and increasing the risk of heart attacks and strokes.
BackgroundCoronary artery bypass grafting (CABG) surgery has been a widely accepted method for treating coronaryarterydisease. However, its postoperative complications can have a significant effect on long-term patient outcomes.
Stroke, Volume 54, Issue 12 , Page 3182-3189, December 1, 2023. The identification of a variant in theHDAC9gene as a risk factor for large-artery atherosclerotic stroke, and subsequently coronaryarterydisease, has opened novel treatment pathways for stroke and more widely atherosclerotic disease.
Stroke, Volume 55, Issue Suppl_1 , Page ATP281-ATP281, February 1, 2024. Patients with prior history of stroke or TIA were excluded. Of 136, 10 (7.4%) were admitted with an acute stroke. There were no differences in age, gender, or race/ethnicity between those who had a stroke versus those that did not.
A person’s LAA may create issues including atrial fibrillation and stroke. He was diagnosed with extensive coronaryarterydisease, resulting in ischemic cardiomyopathy and heart failure. His heart was weak and did not pump well due to blockages in his coronaryarteries. on November 27.
Stroke, Volume 55, Issue Suppl_1 , Page AWP241-AWP241, February 1, 2024. Background:Migraine with aura is a risk factor for ischemic stroke. We refined the migraine with aura risk score (MARS) to create the migraine associated risk of stroke score (MARS Plus) making it applicable to migraine with and without aura.
Stroke, Volume 56, Issue Suppl_1 , Page A53-A53, February 1, 2025. Background:Nearly one-quarter of ischemic strokes (IS) in the U.S. vs 43.8%, p= 0.009), have higher rates of coronaryarterydisease (23.4% are recurrent. Those with LV ejection fraction <30% were not eligible. cm, p=0.028).
Stroke, Volume 56, Issue Suppl_1 , Page ATP283-ATP283, February 1, 2025. Of the 32 who had a stroke event, 24 had ischemic strokes, 7 hemorrhagic, and 1 of unknown mechanism. Of the 32 who had a stroke event, 24 had ischemic strokes, 7 hemorrhagic, and 1 of unknown mechanism. Conclusions:CVA occurred in 1.4%
Stroke, Volume 56, Issue Suppl_1 , Page A140-A140, February 1, 2025. Background:Nearly one-quarter of ischemic strokes (IS) in the U.S. vs 23.8%, p<0.001), and to have coronaryarterydisease (25.7% The incidence rates of recurrent stroke per 100 person-years were 7.1 (95% are recurrent.
Stroke, Volume 55, Issue Suppl_1 , Page A96-A96, February 1, 2024. Introduction:While ischemic stroke (IS) in the young (18-55) is thought to have different etiologies than in older patients, a rise in vascular risk factors (VRFs) among young adults may translate to an IS risk profile similar to the older population. p <0.001).VRF
Stroke, Volume 55, Issue Suppl_1 , Page ATMP40-ATMP40, February 1, 2024. Introduction:The consequences of increased morbidity and increased socioeconomic strain, for stroke survivors and their families, is well documented in stroke literature worldwide. and p=0.01, respectively. and p=0.01, respectively.
Stroke, Volume 55, Issue Suppl_1 , Page A100-A100, February 1, 2024. Introduction:Cervical artery dissection (CAD) is a frequent cause of acute ischemic stroke (AIS) in young adults. female), 215 (1.5%) had subsequent AIS within 90 days of discharge with the median stroke occurrence on day 8.
Stroke, Volume 55, Issue Suppl_1 , Page AWP270-AWP270, February 1, 2024. It has recently been associated with cardiovascular disease and stroke. In the multivariate analysis, the TET2 mutation was associated with CE etiology after adjusting by age, coronaryarterydisease, and classic cardiovascular risk factors (OR 8.1;
Stroke, Volume 55, Issue Suppl_1 , Page ATP236-ATP236, February 1, 2024. Introduction:A rising prevalence of stroke in young patients was noticed in recent years. Studies have reported racial disparities in young stroke patients and less desired outcomes of minorities. were male, and 60.4% vs. Hispanic 12.4%).
Stroke, Volume 55, Issue Suppl_1 , Page A53-A53, February 1, 2024. Introduction:Mechanical Thrombectomy improves outcomes in patients with acute ischemic stroke due to large vessel occlusion. Data on demographics and baseline risk factors, occlusion site, and acute treatment was pulled from the stroke registry. 1.82, p = 0.703).Conclusion:In
Stroke, Volume 56, Issue Suppl_1 , Page A16-A16, February 1, 2025. Background:Colchicine has shown to reduce major adverse cardiovascular events and stroke among patients with coronaryarterydisease. < 6 months) shows comparable risk of stroke compared with placebo (OR, 0.98 (95%CI: 0.82-1.16).
Stroke, Volume 56, Issue 4 , Page e114-e118, April 1, 2025. Intracranial atherosclerotic stenosis is a leading cause of stroke with a significant risk of recurrent ischemic events despite aggressive medical management.
Stroke, Volume 56, Issue Suppl_1 , Page ATP273-ATP273, February 1, 2025. Introduction:Patients suffering from transient ischemic attack (TIA) are at high risk of ischemic stroke (IS). Patients were mostly women (57.6% in MarketScan, 59.3% Median follow-up time was 569 days in MarketScan and 716 days in CDM. respectively, in CDM.
Stroke, Volume 55, Issue Suppl_1 , Page A52-A52, February 1, 2024. Background/Purpose:Stroke imposes a substantial healthcare burden, with ischemic stroke (IS) mortality rising from 2.04 million by 2030 according to the Global Burden of Disease Study. to 2.26) and liver disease (OR 2.20, p < 0.01, CI 1.27
Stroke, Volume 55, Issue Suppl_1 , Page AWP244-AWP244, February 1, 2024. Introduction:Cervical artery dissection (CAD) and acute ischemic stroke (AIS) are key health challenges. Conclusion:This analysis reveals stroke patients are nearly two-fold more likely to have subsequent MI compared to those with CAD.
Stroke, Volume 56, Issue Suppl_1 , Page AWP6-AWP6, February 1, 2025. Background and Purpose:Whether imaging markers of cerebral small vessel disease on computed tomography (CT-CSVD) relates to early clinical outcomes after intravenous thrombolysis for acute ischemic stroke remains not well understood. 1.95, p = 0.019).Conclusion:This
Using mediation Mendelian randomization, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronaryarterydisease, large artery atherosclerotic stroke, and peripheral arterydisease.
This study investigated the long-term risk of cardiovascular disease events in individuals with home SBP <125 versus 125 to <135 or ≥135 mm Hg who participated in the J-HOP study (Japan Morning Surge-Home Blood Pressure).METHODS:The 2.00] for overall cardiovascular disease and 2.68 [95% CI, 1.34–5.38]
Similar results were noted for both coronaryarterydisease and ischemic stroke. It was seen that protection associated with stair climbing was attenuated by increasing levels of disease susceptibility like family history and 10 year risk. Median follow up period was 12.5
Objective To investigate the impact of prior coronaryartery bypass grafting (CABG) and coronary lesion complexity on transcatheter aortic valve replacement (TAVR) outcomes for aortic stenosis. The impact of the CABG SYNTAX score was also evaluated in patients with prior CABG.
Compared with the PVI group, patients in the PVI+SVCI group had a higher prevalence of coronaryarterydisease (p=0.04), stroke (p=0.02) and a smaller left atrial diameter (p<0.01). Results A total of 246 patients were enrolled, with 108 patients in the PVI group and 138 patients in the PVI+SVCI group.
The main outcome was hospitalisation for coronaryarterydisease, ischaemic stroke and other cardiovascular outcomes during 33 years of follow-up. We compared patients with cardiac and non-cardiac birth defects of the urinary, central nervous and other systems against patients without defects between 1989 and 2022.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content